ResultsIQ

ResultsIQ › Latest results › Procter & Gamble Health Limited

Procter & Gamble Health Limited Q1 FY26 results press release summary

NSE: PGHL · BSE: 500126

Results press release of 1 Aug 2025, summarised by AI from the filing.

P&G Health Q1 FY26 sales ₹333 cr, up 20%, PAT ₹66 cr versus ₹17 cr a year ago.

Key takeaways

  1. Sales ₹333 cr, up 20% versus a year ago, on broad-based growth in domestic and exports business.
  2. PAT ₹66 cr versus ₹17 cr a year ago, due to strong sales growth and one-time impact of impairment in the base period.
  3. Growth driver Broad-based growth in domestic and exports business drove the sales increase.
  4. Strategy Focused portfolio of quality, trusted, highly recommended brands, superiority and constructive disruption delivering balanced and sustainable growth.
  5. Base effect PAT comparison reflects one-time impact of impairment in the base period.

Original filing on BSE

Procter & Gamble Health Limited Q1 FY27 results

As filed: Revenue ₹364 cr (+7% year on year), EBITDA ₹99.6 cr (+11% year on year), PAT ₹96.2 cr (+9% year on year), EBITDA margin 27.4% (+84 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹370 cr (+19% year on year), EBITDA ₹136 cr (+67% year on year), PAT ₹94.6 cr (+55% year on year), EBITDA margin 36.6% (+1,000 bps). Score 81 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 1000 bps year on year. Profit rose ₹33.6 cr on a year ago, more than the ₹14.0 cr it added the year before. Share price after the results: +10.3% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹374 cr (+21% year on year), EBITDA ₹110 cr (−11% year on year), PAT ₹77.6 cr (−15% year on year), EBITDA margin 29.6% (−1,000 bps). Score 44 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 1000 bps year on year. Profit fell 13% from last quarter. Share price after the results: −6.8% in 28 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹325 cr (+4% year on year), EBITDA ₹120 cr (+5% year on year), PAT ₹89.0 cr (+9% year on year), EBITDA margin 36.9% (+50 bps). Score 44 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 50 bps year on year. Revenue fell 4% from last quarter. Share price after the results: −5.8% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹339 cr (+19% year on year), EBITDA ₹90.0 cr (+88% year on year), PAT ₹66.0 cr (+288% year on year), EBITDA margin 26.6% (+965 bps). Score 90 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 965 bps year on year. Share price after the results: +8.0% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹311 cr (+23% year on year), EBITDA ₹81.0 cr (+19% year on year), PAT ₹61.0 cr (+30% year on year), EBITDA margin 26.1% (−94 bps). Score 71 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin fell 94 bps year on year. Profit fell 33% from last quarter. Share price after the results: +1.5% in 29 days (Nifty 500: +3.3%).
  • Q3 FY25: Revenue ₹310 cr (0% year on year), EBITDA ₹124 cr (+22% year on year), PAT ₹91.0 cr (+26% year on year), EBITDA margin 40.0% (+710 bps). Score 65 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 710 bps year on year.
  • Q2 FY25: Revenue ₹313 cr (+3% year on year), EBITDA ₹114 cr (+30% year on year), PAT ₹82.0 cr (+24% year on year), EBITDA margin 36.4% (+757 bps). Score 61 of 100, In line with trend. EBITDA margin rose 757 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Procter & Gamble Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.